Update on coxsackievirus B3 myocarditis

Current Opinion in Rheumatology

Volumn 24, Issue 4, 2012, Pages 401-407

  Fairweather, Delisa ^a   Stafford, Katelyn A ^a   Sung, Yoon K ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

autoimmune disease; coxsackievirus; myocarditis; T helper response

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 33; INTERLEUKIN 4; MYOSIN;

AUTOIMMUNE DISEASE; AUTOIMMUNE MYOCARDITIS; CONGESTIVE CARDIOMYOPATHY; COXSACKIE VIRUS B3; COXSACKIE VIRUS B3 MYOCARDITIS; DISEASE COURSE; GENETIC SUSCEPTIBILITY; HEART MUSCLE NECROSIS; HUMAN; IMMUNE RESPONSE; MACROPHAGE; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH2 CELL; VIRUS MYOCARDITIS; VIRUS REPLICATION;

ANIMALS; AUTOIMMUNE DISEASES; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; ENTEROVIRUS B, HUMAN; MICE; MYOCARDITIS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84862146356     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328353372d     Document Type: Review

References (62)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011; 104:276-308.
2. Cooper LT Jr. Myocarditis. N Engl J Med 2009; 360:1526-1538.
3. Wexler RK, Elton T, Pleister A, Feldman D. Cardiomyopathy: an overview. Am Fam Physician 2009; 79:778-784.
4. Gupta S, Markham DW, Drazner MH, Mammen PPA. Fulminant myocarditis. Nat Clin Practice 2008; 5:693-706.
5. Schultheiss HP, Kuhl U, Cooper LT. The management of myocarditis. Eur Heart J 2011; 32:2616-2625.
6. Schultheiss HP, Kuhl U. Why is diagnosis of infectious myocarditis such a challenge? Expert Rev Anti Infect Ther 2011; 9:1093-1095.
7. Kuhl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107:2793-2798. (Pubitemid 36705988)
8. Wang Y-X, da Cunha V, Vincelette J, et al. Antiviral and myocyte protective effects of murine interferon-b and-a2 in coxsackievirus B3-induced myocarditis and epicarditis in BALB/c mice. Am J PhysiolHeart Circ Physiol 2007; 293:H69-H76. (Pubitemid 47105060)
9. Huber SA. Autoimmunity in coxsackievirus B3 induced myocarditis. Autoimm 2006; 39:55-61. (Pubitemid 43878520)
10. Fairweather D, Rose NR. Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods 2007; 41:118-122. (Pubitemid 44855640)
11. Ellis NM, Kurahara DK, Vohra H, et al. Priming the immune system for heart disease: a perspective on group A streptococci. J Infect Dis 2010; 202:1059-1067.
12. Fairweather D, Kaya Z, Shellam GR, et al. From infection to autoimmunity. J Autoimm 2001; 16:175-186. (Pubitemid 32566105)
13. Gauntt C, Huber S. Coxsackievirus experimental heart diseases. Front Biosci 2003; 8:e23-e35.
14. McNamara DM, Starling RC, Cooper LT, et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coll Cardiol 2011; 58:1112-1118.
15. Onyimba JA, Coronado MJ, Garton AE, et al. The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice. Biol Sex Differ 2011; 2:2.
16. Frisancho-Kiss S, Davis SE, Nyland JF, et al. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol 2007; 178:6710-6714. (Pubitemid 46847392)
17. Huber SA, Job LP. Cellular immune mechanisms in coxsackievirus group B, type 3 induced myocarditis in BALB/c mice. Adv Exp Med Biol 1983; 161:491-508.
18. Cihakova D, Barin JG, Afanasyeva M, et al. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol 2008; 172:1195-1208. (Pubitemid 351671534)
19. Huber SA, Sartini D, Exley M. Vgamma4( +) T cells promote autoimmune CD8( +) cytolytic T-lymphocyte activation in coxsackievirus B3-induced myocarditis in mice: role for CD4( +) Th1 cells. J Virol 2002; 76:10785-10790. (Pubitemid 35176195)
20. Noutsias M, Rohde M, Goldner K, et al. Expression of functional T-cell markers and T-cell receptor Vbeta repertoire in endomyocardial biopsies from patients presenting with acute myocarditis and dilated cardiomyopathy. Eur J Heart Fail 2011; 13:611-618.
21. Yuan J, Cao AL, Yu M, et al. Th17 cells facilitate the humoral immune response in patients with acute viral myocarditis. J Clin Immunol 2010; 30:226-234.
22. Baldeviano GC, Barin JG, Talor MV, et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res 2010; 106:1646-1655.
23. Afanasyeva M, Wang Y, Kaya Z, et al. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am J Pathol 2001; 159:193-203. (Pubitemid 33704204)
24. Fairweather D, Frisancho-Kiss S, Yusung SA, et al. IFN-g protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines TGF-b1, IL-1b, and IL-4 in the heart. Am J Pathol 2004; 165:1883-1894. (Pubitemid 39578368)
25. Abston ED, Coronado MJ, Bucek A, et al. Th2 regulation of viral myocarditis in mice: different roles for TLR3 vs. TRIF in progression to chronic disease. Clin Dev Immunol 2012; 2012:129486.
26. Woodruff JF, Woodruff JJ. Involvement of T lymphocytes in the pathogenesis of coxsackievirus B3 heart disease. J Immunol 1974; 113:1726-1734.
27. Huber SA, Job LP, Woodruff JF. Sex-related differences in the pattern of coxsackievirus B3-induced immune spleen cell cytotoxicity against virusinfected myofibers. Infect Immun 1981; 32:68-73. (Pubitemid 11156904)
28. Huber SA. Increased susceptibility of male BALB/c mice to coxsackievirus B3-induced myocarditis: role for CD1d. Med Microbiol Immunol 2005; 194:121-127. (Pubitemid 41202528)
29. Li K, Xu W, Guo Q, et al. Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ Res 2009; 105:353-364.
30. Liu W, Huber S. Cross-talk between CD1d-restricted NKT cells and gd cells in T regulatory cell response. Virol J 2011; 8:32.
31. Cihakova D, Sharma R, Fairweather D, et al. Animal models for autoimmune myocarditis and autoimmune thyroiditis. Methods Mol Med Autoimmunity 2004; 102:175-194.
32. Barin JG, Rose NR, Cihakova D. Macrophage diversity in cardiac inflammation: a review. Immunobiol 2011; [Epub ahead of print].
33. Rose NR. Critical cytokine pathways to cardiac inflammation. J Interferon Cytokine Res 2011; 31:705-710.
34. Afanasyeva M, Georgakopoulos D, Belardi DF, et al. Impaired up-regulation of CD25 on CD4 +T cells in IFN-gamma knockout mice is associated with progression of myocarditis to heart failure. Proc Natl Acad Sci USA 2004; 102:180-185. (Pubitemid 40094449)
35. Afanasyeva M, Georgakopoulos D, Fairweather D, et al. A novel model of constrictive pericarditis associated with autoimmune heart disease in interferon-g knockout mice. Circulation 2004; 110:2910-2917. (Pubitemid 39473617)
36. Coronado MJ, Brandt JE, Kim E et al. Testosterone and interleukin-1b increase cardiac remodeling during acute coxsackievirus B3 myocarditis via serpin A 3n. Am J Physiol Heart Circ Physiol 2012; [Epub ahead of print]
37. Yajima T. Viral myocarditis: potential defense mechanisms within the cardiomyocyte against virus infection. Future Microbiol 2011; 6:551-566.
38. Marchant DJ, Boyd JH, Lin DC, et al. Inflammation in myocardial diseases. Circ Res 2012; 110:126-144.
39. Wiltshire S, Leiva-Torres G, Vidal S. Quantitative trait locus analysis, pathway analysis, and consomic mapping show genetic variants of Tnni3k, Fpgt, or H28 control susceptibility to viral myocarditis. J Immunol 2011; 186:6398-6405.
40. Riad A, Westermann D, Zietsch C, et al. TRIF is a critical survival factor in viral cardiomyopathy. J Immunol 2011; 186:2561-2570.
41. Fairweather D, Frisancho-Kiss S, Yusung SA, et al. IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-g and macrophage and neutrophil populations in the heart. J Immunol 2005; 174:261-269. (Pubitemid 40007412)
42. Burke J, Sonenberg N, Platanias L, Fish E. Antiviral effects of interferon-b are enhanced in the absence of the translational suppressor 4E-BP1 in myocarditis induced by coxackievirus B3. Antivir Ther 2011; 16:577-584.
43. Xu Z, Desai M, Philip J, et al. Conditional transgenic expression of TIR-domaincontaining adaptor-inducing interferon-b (TRIF) in the adult mouse heart is protective in acute viral myocarditis. Basic Res Cardiol 2011; 106:1159-1171.
44. Yu Z, Huang Z, Shao C, et al. Oral administration of interferon-a2b- transformed Bifidobacterium longum protects BALB/c mice against coxsackievirus B3-induced myocarditis. Virol J 2011; 8:525.
45. Yue Y, Gui J, Ai W, et al. Direct gene transfer with IP-10 mutant ameliorates mouse CVB3-induced myocarditis by blunting Th1 immune responses. PLoS ONE 2011; 6:e18186.
46. Yue Y, Gui J, Xu W, Xiong S. Gene therapy with CCL2 (MCP-1) mutant protects CVB3-induced myocarditis by compromising Th1 polarization. Mol Immunol 2011; 48:706-713.
47. Miteva K, Haag M, Peng J, et al. Human cardiac-derived adherent proliferating cells reduce murine acute coxsackievirus B3-induced myocarditis. PLoS ONE 2011; 6:e28513.
48. Van Linthout S, Savvatis K, Miteva K, et al. Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis. Eur Heart J 2011; 32:2168-2178.
49. Case L, Moussawi M, Roberts B, et al. Histamine H(1) receptor signaling regulates effector T cell responses and susceptibility to coxsackievirus B3-induced myocarditis. Cell Immunol 2012; 272:269-274.
50. Fousteri G, Dave A, Morin B, et al. Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J Autoimm 2011; 36:210-220.
51. Frisancho-Kiss S, Nyland JF, Davis SE, et al. Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity. J Immunol 2006; 176:6411-6415. (Pubitemid 43787822)
52. Lv K, Xu W, Wang C, et al. Galectin-9 administration ameliorates CVB3 induced myocarditis by promoting the proliferation of regulatory T cells and alternatively activated Th2 cells. Clin Immunol 2011; 140:92-101.
53. Chen P, Xie Y, Shen E, et al. Astragaloside IV attenuates myocardial fibrosis by inhibiting TGF-b1 signaling in coxsackievirus B3-induced cardiomyopathy. Eur J Pharmacol 2011; 658:168-174.
54. Yuan J, Yu M, Lin QW, et al. Neutralization of IL-17 inhibits the production of anti-ANT autoantibodies in CVB3-induced acute viral myocarditis. Int Immunopharmacol 2010; 10:272-276.
55. Yuan J, Yu M, Lin QW, et al. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol 2010; 185:4004-4010.
56. Yang F, Wu W-F, Yan Y-L, et al. Expression of IL-23/Th17 pathway in a murine model of coxsackie virus B3-induced viral myocarditis. Virol J 2011; 8:301.
57. Qing K, Weifeng W, Fan Y, et al. Distinct different expression of Th17 and Th9 cells in coxsackievirus B3-induced mice viral myocarditis. Virol J 2011; 8:267.
58. Xie Y, Chen R, Zhang X, et al. The role of Th17 cells and regulatory T cells in coxsackievirus B3-induced myocarditis. Virology 2011; 421:78-84.
59. Xie Y, Chen R, Zhang X et al. Blockade of interleukin-17A protects against coxsackievirus B3-induced myocarditis by increasing COX-2/PGE2 production in the heart. FEMS Immunol Med Microbiol 2011; [Epub ahead of print].
60. Fan Y, Weifeng W, Yuluan Y, et al. Treatment with a neutralizing antimurine interleukin-17 antibody after the onset of coxsackievirus B3-induced viral myocarditis reduces myocardium inflammation. Virol J 2011; 8:17.
61. Nyland JF, Fairweather D, Shirley DL, et al. Low dose inorganic mercury increases severity and frequency of chronic coxsackievirus-induced autoimmune myocarditis in mice. Toxicol Sci 2011; 125:134-143.
62. Su Z, Sun C, Zhou C, et al. HMGB 1 blockade attenuates experimental autoimmune myocarditis possibly by suppressing Th17-cell expansion. Eur J Immunol 2011; 9:3586-3595.